ATE464908T1 - Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern - Google Patents

Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern

Info

Publication number
ATE464908T1
ATE464908T1 AT05702390T AT05702390T ATE464908T1 AT E464908 T1 ATE464908 T1 AT E464908T1 AT 05702390 T AT05702390 T AT 05702390T AT 05702390 T AT05702390 T AT 05702390T AT E464908 T1 ATE464908 T1 AT E464908T1
Authority
AT
Austria
Prior art keywords
antibodies
treating osteoarthritis
osteoarthritis
treating
antagonists
Prior art date
Application number
AT05702390T
Other languages
English (en)
Inventor
Susan Elizabeth Bove
Kenneth Stanley Kilgore
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE464908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE464908T1 publication Critical patent/ATE464908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AT05702390T 2004-02-11 2005-01-31 Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern ATE464908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54381404P 2004-02-11 2004-02-11
PCT/IB2005/000240 WO2005080429A2 (en) 2004-02-11 2005-01-31 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies

Publications (1)

Publication Number Publication Date
ATE464908T1 true ATE464908T1 (de) 2010-05-15

Family

ID=34885980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05702390T ATE464908T1 (de) 2004-02-11 2005-01-31 Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern

Country Status (9)

Country Link
US (2) US20080145367A1 (de)
EP (1) EP1715891B2 (de)
JP (1) JP2008505054A (de)
AT (1) ATE464908T1 (de)
BR (1) BRPI0506679A (de)
CA (1) CA2555688C (de)
DE (1) DE602005020743D1 (de)
ES (1) ES2341461T5 (de)
WO (1) WO2005080429A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
JP2009545319A (ja) 2006-08-03 2009-12-24 バクシネックス，インコーポレーテッド 抗ｉｌ−６モノクローナル抗体およびその使用
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2009010539A2 (de) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) form macaca fascicularis
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010071924A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Osteoarthritis treatment
TWI440470B (zh) * 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd 含改良抗體分子之醫藥配方
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN103596591B (zh) * 2011-02-08 2016-08-24 Abbvie公司 骨关节炎和疼痛的治疗
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013081143A1 (ja) 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
EP3009518B1 (de) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Verfahren zur vorhersage einer posttherapeutischen prognose von patienten mit schubförmig remittierender multipler sklerose (rrms) und verfahren zur bestimmung der anwendbarkeit der neuartigen therapie
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP3194025A4 (de) * 2014-09-18 2018-05-23 Rush University Medical Center Verfahren zur prävention oder behandlung von osteoarthritis
PE20221834A1 (es) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016186154A1 (ja) 2015-05-19 2016-11-24 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
JP2018529756A (ja) 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
EP3576790A4 (de) 2017-02-01 2020-12-23 Yale University Behandlung von diuretischer resistenz
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
BR112020013519A2 (pt) 2018-01-05 2020-12-01 Corvidia Therapeutics, Inc método para tratamento de uma inflamação.
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT52962A (en) * 1988-03-04 1990-09-28 Sandoz Ag Process for production of medical compositions eliminating bone-absorption and promoting forming of bones
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP2077120A3 (de) * 1994-10-07 2009-07-15 Chugai Seiyaku Kabushiki Kaisha Heilmittel für rheumatoide Arthritis mit IL-6-Antagonisten als Aktivsubstanz
US5617790A (en) * 1995-05-31 1997-04-08 P.R. Graphics Limited Apparatus for producing flexographic printing plates
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
CN100374457C (zh) * 2001-11-14 2008-03-12 森托科尔公司 抗il-6抗体、组合物、方法和用途

Also Published As

Publication number Publication date
CA2555688A1 (en) 2005-09-01
CA2555688C (en) 2011-11-08
EP1715891B1 (de) 2010-04-21
ES2341461T3 (es) 2010-06-21
JP2008505054A (ja) 2008-02-21
US20080145367A1 (en) 2008-06-19
US20100215654A1 (en) 2010-08-26
EP1715891A2 (de) 2006-11-02
ES2341461T5 (es) 2014-10-29
DE602005020743D1 (de) 2010-06-02
WO2005080429A2 (en) 2005-09-01
EP1715891B2 (de) 2014-08-13
WO2005080429A3 (en) 2006-02-23
BRPI0506679A (pt) 2007-05-15

Similar Documents

Publication Publication Date Title
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
DE502004009142D1 (de) Verfahren zur herstellung substituierter 3-aryl-butyl-aminverbindungen
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE550353T1 (de) Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
DE602004032160D1 (de) Verfahren zur Zubereitung von Getränken
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
DE502005002345D1 (de) Verfahren zur einstellung von sitzkomponenten
DE602005012170D1 (de) Verfahren zur Herstellung von granuliertem L-Lysin enthaltendem Futterzusatz
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
DE602007001103D1 (de) Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
DE502005000987D1 (de) Verfahren zur kontinuierlichen herstellung von siilicon emulsionen
DE602004000313D1 (de) Verfahren zur Verfügungstellung von ozonenthaltendem Wasser
DE60232956D1 (de) Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
DE602005021766D1 (de) Verfahren zur behandlung von atherosklerose
DE602006002371D1 (de) Verfahren zur herstellung von brillengläsern
ATE546524T1 (de) Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties